SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending after releasing positive Phase 3 trial results for their DMD treatment, showing statistically significant improvement in both skeletal and cardiac function. The community is buzzing about the potential for FDA approval and a possible buyout by a major pharmaceutical company, with many expressing excitement about the implications for treating this rare disease. Short sellers are feeling the squeeze, as the stock experiences high volatility and a surge in trading volume.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai ($AI) is trending amid discussions around its valuation compared to peers and potential for a short squeeze, as well as speculation about a possible acquisition. Community members are weighing the company's financials and contracts, with some expressing bullish sentiment and others remaining skeptical about its long-term prospects. Option activity and potential price movements are also being closely monitored by traders.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending as the robotics sector gains attention, fueled by reports of potential government support and media coverage. Community discussions revolve around the stock's overnight price action, high short interest creating squeeze potential, and comparing SERV to other robotics plays like RR and IRBT. Some traders are citing the recent DoorDash partnership as a key catalyst for future growth, while others express concerns about recent price volatility.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

PLRZ is trending due to positive preclinical data for its intranasal naloxone hydrogel, with the community noting its potential as a multi-day runner. Community members are actively discussing price targets and potential short squeezes, drawing comparisons to other low-float Israeli stocks that have recently experienced significant gains. However, some are expressing caution due to the company's history of reverse splits and dilution, as well as an upcoming clinical trial not expected to start until 2026.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics is trending as investors closely monitor the company's progress towards potential FDA feedback and a possible buyout or partnership. Community discussions highlight positive data readouts and increased excitement from the CEO, fueling speculation about the future of Belapectin. Investors are also paying attention to short positions and trading activity, anticipating a potential short squeeze.

Breaking Bread is a pioneer in Solana meme token designed around a simple and transparent rewards system. With 0% tax on trades, every holder benefits directly from activity without hidden costs or penalties. The token automatically redistributes 100% of creator rewards from Pump.fun back to the community, ensuring fair participation for all holders. The project emphasizes consistency, trust, and community engagement, framing daily “breaking of bread” rewards as both a symbolic ritual and a practical way to sustain value for those who participate.

Breaking Bread

Breaking Bread ($BRBR) is gaining traction as a Solana meme coin with a unique reward system, distributing $SOL to holders based on volume, attracting users seeking real yield. The community is actively discussing the coin's innovative approach of zero taxes on trades and the distribution of creator rewards directly to holders, fostering a strong sense of community and long-term investment potential. With a focus on rewarding holders, $BRBR aims to differentiate itself in the crowded meme coin space.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

CVKD is trending as investors discuss recent news, including analyst coverage and progress in Phase 3 trials for Tecarfarin, which targets a multi-billion dollar market. Community chatter highlights both bullish perspectives and concerns about dilution and past performance. Bullish investors focus on the potential of Tecarfarin, its FDA Fast Track status, and collaborations, while bears point to past struggles and financial risks.

The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children’s Place, Baby Place, and Gymboree. It operates through The Children’s Place U.S. and The Children’s Place International segments. The Children’s Place U.S. segment refers to the company’s U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children’s Place International segment is involved in the Canadian-based stores, revenue from the company’s Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.

Childrens Place Inc

$PLCE is gaining attention due to unusual options activity and speculation about an upcoming earnings surprise, with community members actively discussing potential short squeezes and the impact of institutional ownership. The stock's low market cap relative to its revenue and high short interest are fueling optimism for a significant price increase. Some traders point to the company's turnaround efforts and potential for increased profitability as bullish signals.

ProShares Trust - ProShares Ultra Ether ETF

ProShares Ultra Ether ETF

ETHT is trending as traders discuss Ethereum's potential rally and recent price consolidation, with some anticipating a breakout. Bullish sentiment is fueled by technical analysis suggesting increasing upward momentum, while others point to potential profit-taking opportunities. Community members are actively sharing options strategies and expressing varied opinions on the ETF's tracking accuracy relative to Ethereum's price movements.

Aeva Technologies, Inc. develops sensing paradigm for autonomous vehicles and robotics. The firm offers drones, robotics, vehicle technology, and virtual and augmented reality products. The company was founded by Soroush Salehian Dardashti and Mina Rezk in 2017 and is headquartered in Mountain View, CA.

Aeva Technologies Inc

AEVA is trending due to a recent partnership with LG Innotek for LiDAR technology development, sparking discussions about its potential in automotive and other sectors. The community is weighing its high valuation against its growth prospects, comparing it to competitors like INVZ and OUST. Some investors are expressing concerns about cash burn and insider selling, while others remain bullish on its technology and long-term potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
